A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis

This is a phase 3, multi-center, prospective, open-label, single-arm, clinical trial to be carried out in subjects with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia.
This clinical trial is planned to be performed at study sites in multiple countries. It is planned to include a maximum of 32 adult and pediatric subjects with congenital fibrinogen deficiency in order to provide at least 28 evaluable acute bleeding episodes and/or surgical procedures.

开始日期2023-12-01

申办/合作机构

Instituto Grifols SA

LBCTR2021024523 / Suspended临床3期

A prospective, multicenter, open-label, single-arm study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia requiring either ondemand treatment for acute bleeding or surgical prophylaxis - NA

开始日期2020-10-12

申办/合作机构

Instituto Grifols SA

NCT04356781 / RecruitingN/AIIT

Do (IgG) Variations in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) and MMN Patients Following Initial Intravenous Immunoglobulin (IVIg) Treatment Correlate With Ultimate Dosing

CIDP and MMN are part of a group of chronic inflammatory conditions that affect the peripheral nervous system. In CIDP, there is chronic inflammation of the peripheral nerves and nerve roots leading to demyelination. The myelin sheath is vital in the rapid propagation of nerve impulses between the central nervous system and the peripheral sensory receptors and muscles. By definition CIDP must progress over 8 or more weeks and can either have a slowly progressive disease course or a relapsing course with periods of improvement. Patients typically present with a non-length dependent neuropathy that affects motor (i.e. weakness of proximal or distal muscles, fatigue, swallowing difficulty, double vision, breathing difficulties etc) and sensory function.
MMN is a similar condition to CIDP. It is an autoimmune demyelinating neuropathy that leads to slowly progressive asymmetrical weakness that worsens over years without treatment.
IVIg is a recognised treatment for CIDP and MMN. A standard starting dose of 2 g/kg/course, spread over 2-5 days, has been widely used in both research and clinical practice. Due to the chronic nature of CIDP and MMN, most patients with these conditions require repeated doses to avoid relapse, but the frequency of courses and the total dose of IVIg per course required to achieve a steady state varies between patients. Given the modest risks involved with IVIg and its cost, the lowest possible dose and frequency of administration are preferred. Current strategies to reduce dose and frequency involve assessing clinical response to lower doses, but this is both time consuming and imprecise.

开始日期2020-09-28

申办/合作机构

The Walton Centre NHS Foundation Trust

[+1]

100 项与 Instituto Grifols SA 相关的临床结果

登录后查看更多信息

0 项与 Instituto Grifols SA 相关的专利（医药）

登录后查看更多信息

项与 Instituto Grifols SA 相关的文献（医药）

2024-11-01·JOURNAL OF PEDIATRIC SURGERY

A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery

Article

作者: Slavkovic, Andjelka ; Balanescu, Laura ; Camprubí, Sandra ; Hanna, Kim ; James, Michael K. ; Jenovari, Zoltan ; Querolt, Montse ; Gajdobranski, Djordje ; Mikickovic, Maja ; Bozzo, Jordi ; Kamenov, Krasimir ; Vajda, Péter ; Camprubí, Sandra ; Irtan, Sabine ; Querolt, Montse ; Mondou, Elsa ; Mondou, Elsa ; Kalinova, Krasimira ; Ninov, Borislav ; Sharif, Khalid ; Simeonov, Simeon ; Sretenović, Aleksandar ; Wiener, Isodoro ; Hanna, Kim

BACKGROUND:

In this study, two fibrin sealant products, Fibrin Sealant Grifols (FS Grifols 80 mg/mL fibrinogen; 500 IU/mL thrombin) and Evicel (fibrinogen 55-85 mg/mL; thrombin 800-1200 IU/mL) were studied for efficacy in achieving hemostasis at a targeted bleeding site (TBS) on parenchymous or soft tissue in pediatric surgeries.

METHODS:

This phase 3, single-blind, active comparator, non-inferiority trial compared the number of patients achieving hemostasis at a TBS at four (T₄ - primary endpoint), seven (T₇) and 10 (T₁₀) minutes after application, Safety and tolerability were assessed by recording adverse events during and after procedures. Eligible patients were <18 years old undergoing elective, open, non-cardiac thoracic, abdominal or pelvic surgeries. Preterm (<37 weeks gestation) and newborn (0-27 days) infants were eligible.

RESULTS:

At T₄, 98.7% of FS Grifols group (n = 91) and 95.4% of the Evicel group (n = 87) achieved hemostasis. All patients with residual bleeding at T₄ were undergoing soft tissue surgery. All patients achieved hemostasis by T₇. At T₁₀, all patients achieved hemostasis except one (FS Grifols (no observation recorded)). There were no incidents of persistent bleeding. For FS Grifols, 26.5% of patients had treatment-emergent adverse events (TEAEs) and 18.4% for Evicel. One TEAE (moderate procedural pain - FS Grifols group) was considered possibly related to study treatment. Three patients died for reasons unrelated to the study medications.

CONCLUSIONS:

FS Grifols was safe and effective at achieving hemostasis in pediatric patients having parenchymous or soft tissue surgeries. The efficacy of FS Grifols was non-inferior to Evicel.

LEVEL OF EVIDENCE:

2017-11-28·Journal of Alzheimer's disease : JAD

Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer’s Disease Patients Treated with Plasma Exchange with 5% Human Albumin

Article

作者: Boada, Mercè ; Páez, Antonio ; Tárraga, Lluís ; Roca, Isabel ; Cuberas-Borrós, Gemma ; Hernández, Isabel ; Torres, Mireia ; Bittini, Ángel ; Núñez, Laura ; Guzmán-de-Villoria, Juan A. ; Rubio, Lourdes ; Pujadas, Francesc ; Torres, Gustavo ; Buendia, Mar ; Castell, Joan

BACKGROUND:

Recently, modifications of Aβ1-42 levels in CSF and plasma associated with improvement in memory and language functions have been observed in patients with mild-moderate Alzheimer's disease (AD) treated with plasma exchange (PE) with albumin replacement.

OBJECTIVE:

To detect structural and functional brain changes in PE-treated AD patients as part of a Phase II clinical trial.

METHODS:

Patients received between 3 and 18 PE with albumin (Albutein® 5%, Grifols) or sham-PE (controls) for 21 weeks (divided in one intensive and two maintenance periods) followed by 6-month follow-up. Brain perfusion assessed by SPECT scans using an automated software (NeuroGam®) and brain structural changes assessed by MRI were performed at weeks 0 (baseline), 21, and 44 (with additional SPECT at weeks 9 and 33). Statistical parametric mapping (voxel-based analysis, SPM) and Z-scores calculations were applied to investigate changes to baseline.

RESULTS:

42 patients were recruited (39 evaluable; 37 analyzed: 18 PE-treated; 19 controls). There was a trend toward decreasing hippocampi and total intracranial volume for both patient groups during the study (p < 0.05). After six months, PE-treated patients had less cerebral perfusion loss than controls in frontal, temporal, and parietal areas, and perfusion stabilization in Brodmann area BA38-R during the PE-treatment period (p < 0.05). SPM analysis showed stabilization or absence of progression of perfusion loss in PE-treated patients until week 21, not observed in controls.

CONCLUSIONS:

Mild-moderate AD patients showed decreased brain volume and impairment of brain perfusion as expected for the progression of the disease. PE-treatment with albumin replacement favored the stabilization of perfusion.

2017-01-12·Journal of Alzheimer's disease : JAD3区 · 医学

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial

3区 · 医学

Article

作者: Ortiz, Pilar ; Anaya, Fernando ; Torres, Mireia ; Hernández, Isabel ; Grifols, Joan Ramon ; Ferrer, Isidre ; Páez, Antonio ; Lopez, Oscar L. ; Boada, Mercè ; Núñez, Laura ; Alegret, Montserrat ; Olazarán, Javier ; Shua-Haim, Joshua R. ; Muñoz, Joan ; Obisesan, Thomas O. ; Lafuente, Asunción ; Buendia, Mar ; Tárraga, Lluís

BACKGROUND:

Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments.

OBJECTIVE:

To determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer's disease (AD).

METHODS:

In a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein®, Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ1-40 and Aβ1-42 levels, as well as cognitive, functional, and behavioral measures were determined.

RESULTS:

CSF Aβ1-42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus -45.5 pg/mL; 95% CI: -19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ1-42 levels were lower in the PE-treated group after each treatment period (p < 0.05). Plasma Aβ1-40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency (p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase (p < 0.05).

CONCLUSION:

PE with human albumin modified CSF and plasma Aβ1-42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued.

项与 Instituto Grifols SA 相关的新闻（医药）

2024-06-13

·医药地理

国家药监局印发血液制品相关行动计划，血液制品销售分析

6月11日，国家药监局综合司印发了《血液制品生产智慧监管三年行动计划（2024—2026年）》。该计划提出，要督促血液制品生产企业严格贯彻落实《药品管理法》《血液制品管理条例》《药品生产监督管理办法》《药品生产质量管理规范（2010年修订）》血液制品附录等法律法规要求，加快血液制品生产、检验环节信息化建设，推动建立覆盖血液制品原料血浆入厂到生产、检验全过程的信息化管理体系。按照率先实施、分批推进的原则，通过三年行动，2026年底前基本实现血液制品生产企业信息化管理，切实提高血液制品监管效能，有力保障血液制品质量安全。图表 1 国家药监局综合司关于印发血液制品生产智慧监管三年行动计划（2024—2026年）的通知图表 2 血液制品生产智慧监管三年行动计划（2024—2026年）.docx 来源：国家药监局血液制品（Blood Products)是由健康人血浆或经特异免疫的人血浆，经分离、提纯或由重组DNA技术制成的血浆蛋白组分，以及血液细胞有形成分统称为血液制品。常见的血液制品有人血白蛋白、人胎盘血白蛋白、静脉注射用人免疫球蛋白、肌注人免疫球蛋白、组织胺人免疫球蛋白、特异性免疫球蛋白、免疫球蛋白（乙型肝炎、狂犬病、破伤风免疫球蛋白）、人凝血因子Ⅷ、人凝血酶原复合物、人纤维蛋白原、抗人淋巴细胞免疫球蛋白等。作为血液的替代品，血液制品有更长的保质期，在某些重大疾病的预防和治疗及医疗急救等方面有着其它药品无法替代的重要作用。图表 3 2018-2023年血液替代品和血浆蛋白组分、其他血液制品国内全渠道放大销售分析来源：PDB药物综合数据库图表 4 2018-2023年血液替代品和血浆蛋白组分、其他血液制品国内全渠道放大销售品种分析来源：PDB药物综合数据库 2018年至2023年，我国血液替代品和血浆蛋白组分、其他血液制品的销售额连续上升。2018年我国血液替代品和血浆蛋白组分、其他血液制品的销售额为146.97亿元，2019年销售额为182.86亿元，2020年销售额204.64亿元，2021年226.86亿元，2022年242.78亿元，2023年销售额达273.93亿元，同比增长率均在7%以上。其中，销售金额最突出的品种是人血白蛋白，销售额占比约82%-90%，也呈逐年上升趋势。人白蛋白（Human albumin）别称人血白蛋白，用经乙型肝炎疫苗免疫的健康人中采集的血浆分离提取，并经60℃、10小时加温灭活病毒后制成。人血白蛋白属于生物制品，是人体的正常组分，占血浆蛋白总量的一半以上。白蛋白最重要的生理作用之一是其血液渗透压维持作用以及对相对分子质量较低物质的运载作用。因此，在临床中，人血白蛋白主要用于纠正血容量不足、维持血浆胶体渗透压。图表 5 2018-2023年人血白蛋白国内全渠道放大销售分析来源：PDB药物综合数据库图表 6 2018-2023年人血白蛋白国内全渠道放大销售企业分析来源：PDB药物综合数据库 2018年至2023年，我国人血白蛋白销售情况与血液替代品和血浆蛋白组分、其他血液制品的销售情况近似，销售额稳定增长，市场规模不断扩大。从企业方面看，CSL Behring A.G.（瑞士杰特贝林）、Takeda Manufacturing Austria A.G.（日本武田制药）、Instituto Grifols, S.A.（西班牙基立福）三家外企业销售额均排在前列。随着我国医药事业的不断发展，临床需求的日益增加，国产人血白蛋白的销售额也在不断增长。2023年，山东泰邦生物制品有限公司人血白蛋白销量突破14亿元，排名第四。此外，成都蓉生药业有限责任公司、四川远大蜀阳药业有限责任公司等国内企业也榜上有名。我国对于血液制品的管控由来已久。1996年12月，国务院发布了《血液制品管理条例》，标志着中国血液制品管理进入法制化轨道。1998年，血液制品行业实行GMP准入制度，只有通过国家药品GMP认证的企业才能生产经营血液制品。2001年，国家规定不再批准新的血液制品生产企业。2002年，国家发布了《生物制品批签发管理办法（试行）》，要求每批制品出厂销售前或者进口时实行强制性审查、检验和批准的制度，进一步保证生物制品安全、有效。此外，国家分别于2007年和2008年开启了原料血浆检疫期管理及单采血浆站管理办法。这一系列政策的发布实施，为血液制品行业的健康发展奠定了坚实的基础。本次印发的《血液制品生产智慧监管三年行动计划（2024—2026年）》，也将推进血液制品产业高质量发展，全面加快推进血液制品生产、检验环节信息化建设等工作，促进血液制品生产转型升级，切实保障血液制品安全、有效和质量可控。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

疫苗核酸药物

2024-05-30

·PRNewswire

Global Surgical Pliers Market to Exhibit Growth at a CAGR of ~5% by 2030 | DelveInsight

The increasing need for surgical pliers is mainly driven by the escalating volume of surgical interventions due to the higher incidence of chronic illnesses and the surging rates of accidents and injuries globally. Additionally, factors such as the expanding presence of surgical facilities, a rising population of elderly patients, growth in the healthcare sector, frequent introduction of new products, and advancements in product design contribute significantly to this demand. LAS VEGAS, May 30, 2024 /PRNewswire/ -- DelveInsight's Surgical Pliers Market Insights report provides the current and forecast market analysis, individual leading surgical pliers companies' market shares, challenges, surgical pliers market drivers, barriers, trends, and key market surgical pliers companies in the market. Key Takeaways from the Surgical Pliers Market Report As per DelveInsight estimates, North America is anticipated to dominate the global surgical pliers market during the forecast period. In the type segment of the surgical pliers market, the reusable category had a significant revenue share in the year 2023. This can be ascribed to the advantages and applications associated with the segment. Notable surgical pliers companies such as Eurotek Surgical Co., Integra LifeSciences, STERIS, Novo Surgical Inc., Sklar Surgical Instruments, Vital Surgical Technologies LLC, Abraham Black Smith, Kapp Surgical GmbH, KALELKER SURGICALS, DTR Medical, and several others, are currently operating in the surgical pliers market. In October 2023, Channellock, Inc. launched its all-new SpeedGrip™ V-Jaw Tongue & Groove Pliers. To read more about the latest highlights related to the surgical pliers market, get a snapshot of the key highlights entailed in the Global Surgical Pliers Market Report Surgical Pliers Overview Surgical pliers are indispensable tools in the medical field, designed with precision and functionality to assist surgeons in a myriad of procedures. These versatile instruments come in various shapes and sizes, tailored to meet specific surgical needs. With their ergonomic design and durable construction, surgical pliers provide surgeons with a firm grip and precise control, essential for delicate maneuvers during operations. Whether used for grasping, holding, cutting, or manipulating tissues and sutures, these specialized pliers play a crucial role in ensuring surgical precision and efficiency. The evolution of surgical pliers reflects advancements in medical technology and the relentless pursuit of safer and more effective surgical techniques. From traditional stainless steel designs to modern iterations featuring specialized coatings and ergonomic handles, these instruments continue to undergo refinements to enhance their performance and usability. With each innovation, surgical pliers empower surgeons to achieve greater accuracy and efficiency, ultimately contributing to improved patient outcomes and the advancement of surgical practice. Surgical Pliers Market Insights In 2023, North America dominated the surgical pliers market, primarily due to several key factors driving growth. These factors include the escalating incidence of chronic ailments, the aging population leading to a higher demand for medical interventions, an upsurge in surgical procedures, a rise in accidents and injuries, consistent strategic collaborations among industry players, increased healthcare spending, and other contributing factors. This trend is expected to continue from 2024 to 2030, indicating a promising outlook for the surgical pliers market in the region. Recent research by the Personalized Orthopedics of the Palm Beaches highlights that in the United States alone, surgical pliers are used approximately 800,000 times annually, with this number steadily increasing each year. According to a 2023 report by the Canadian Institute for Health Information (CIHI), in the 2021-2022 period, over 112,558 female patients underwent cesarean section deliveries, and approximately 51,599 inpatients received knee replacement surgeries in Canada. Additionally, data from the Organisation for Economic Co-operation and Development (OECD) in 2023 reveals that Mexico performed nearly 3,602 total knee replacement surgeries in 2021. Moreover, approximately 980,756 cesarean section procedures were conducted in Mexico during the same year. These statistics underline the growing volume of surgeries in the region, which directly correlates with the demand for surgical pliers. Furthermore, factors such as the increasing prevalence of chronic diseases like cancer, advancements in technology, a rise in awareness initiatives promoting early disease detection, and substantial healthcare expenditure will further fuel the growth of the surgical pliers market in North America throughout the forecast period. To know more about why North America is leading the market growth in the surgical pliers market, get a snapshot of the Surgical Pliers Market Outlook Surgical Pliers Market Dynamics The surgical pliers market dynamics exhibit a blend of technological advancements, evolving healthcare practices, and increasing demand for precision instruments. With the rise in minimally invasive surgical procedures, there's a growing emphasis on specialized pliers designed for intricate tasks. Manufacturers are constantly innovating to meet the demand for ergonomic designs, improved durability, and enhanced functionality, catering to the diverse needs of surgeons across different specialties. Moreover, the global healthcare landscape's transformation, driven by factors such as aging populations and the prevalence of chronic diseases, further fuels the demand for surgical pliers. As healthcare facilities strive to optimize operational efficiency and patient outcomes, they seek advanced tools that offer superior performance and reliability. This trend encourages market players to invest in research and development, fostering the introduction of cutting-edge plier designs equipped with features like enhanced grip, sterilization compatibility, and integration with robotic surgical systems. Furthermore, the competitive landscape of the surgical pliers market is shaped by factors such as regulatory standards, pricing pressures, and strategic partnerships. Adherence to stringent regulatory guidelines is paramount, driving manufacturers to focus on product quality and compliance. Additionally, strategic collaborations with healthcare institutions and distribution networks play a crucial role in market penetration and expansion. Overall, the surgical pliers market remains dynamic, characterized by innovation-driven competition and a constant quest to address evolving clinical needs while maintaining high standards of quality and safety. Get a sneak peek at the surgical pliers market dynamics @ Surgical Pliers Market Dynamics Analysis Surgical Pliers Market Assessment Surgical Pliers Market Segmentation Surgical Pliers Market Segmentation By Type: Disposable and Reusable Surgical Pliers Market Segmentation By Design: Straight, Curved, and Others Surgical Pliers Market Segmentation By Application: Clamping And Occluding, Dissecting And Cutting, Holding And Grasping, and Others Surgical Pliers Market Segmentation By End User: Hospitals & Clinics, Ambulatory Surgical Centers, and Others Surgical Pliers Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the surgical pliers market are set to emerge as the trendsetter explore @ Surgical Pliers Companies Table of Contents Interested in knowing the surgical pliers market by 2030? Click to get a snapshot of the Surgical Pliers Market Trends Related Reports Ambulatory Surgical Centers Market Ambulatory Surgical Centers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key ambulatory surgical centers companies, including AMSURG, Surgical Care Affiliates, HCA Healthcare, Tenet Healthcare, Surgery Partners, Cerner Corporation, United Surgical Partners International, Hunterdon Healthcare, Surg Center Gilbert, Beaumont Health, Ambulatory Surgical Centers of America, Center for Health Ambulatory Surgery Centers, TeamHealth, Pediatrix Medical Group, Quoram Health Corporation, among others. Minimally Invasive Surgical (MIS) Devices Market Minimally Invasive Surgical (MIS) Devices Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key MIS devices companies, including Abbott, Olympus, Intuitive Surgical Inc, Stryker, JOHNSON & JOHNSON MEDICAL DEVICES COMPANIES, Medtronic, Boston Scientific Corporation, CONMED Corporation, KARL STORZ GmbH, CooperSurgical, Inc., Cook, AngioDynamics, FUJIFILM Corporation, Symmetry Surgical Inc, B. Braun Melsungen AG, BD, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Zimmer Biomet, Richard Wolf GmbH, Microport Scientific Corporation, among others. Surgical Bleeding Market Surgical Bleeding Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key surgical bleeding companies, including Mallinckrodt, Dilon Technologies Inc., Syneos Health, Instituto Grifols S.A., Grifols Biologicals LLC, Hemanext, Cubist Pharmaceuticals LLC, Ethicon Inc., OMRIX Biopharmaceuticals, Baxter Healthcare Corporation, among others. Surgical Dressings Market Surgical Dressings Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key surgical dressings companies, including 3M, Coloplast, Mölnlycke Health Care AB, Cardinal Health, Convatec Inc., Smith+Nephew, Argentum Medical, Medline Industries, LP., Advancis Medical, Medical Devices Business Services, Inc., B. Braun SE, Integra LifeSciences, Medtronic, Essity, Organogenesis Inc., Medicare, Alliqua, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

100 项与 Instituto Grifols SA 相关的药物交易

登录后查看更多信息

100 项与 Instituto Grifols SA 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

纤维蛋白粘合剂（Grifols） ( fibrin )	出血更多	批准上市
福他替尼 ( Syk )	免疫性血小板减少症更多	批准上市
Immune Globulin (Human)(Grifols)	脊髓灰质炎后综合征更多	终止
Fibrinogen(Grifols) ( Fibrinogen )	纤维蛋白原缺乏血症更多	终止
Albumin (Human) (Grifols)	阿尔茨海默症更多	无进展